This provides further evidence that targetable FGFR fusions do occur in breast cancer, albeit at low frequency, and adds further weight to emerging evidence highlighting FGFR4 as a potential therapeutic target in this malignancy [28, 29]. Here, FGFR4 is linked to breast cancer.